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Mineralocorticoid Receptor Antagonists in Elderly patients with Heart Failure: A Systematic 
Review and Meta-analysis. 
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Background: Mineralocorticoid receptor antagonists (MRAs) improve outcomes in several populations 
of patients with heart failure (HF) but there has been no systematic review of MRAs in older patients.  
Objectives: Systematic review and meta-analysis of the efficacy and safety of MRA treatment in elderly 
HF patients. 
Data sources: Trials were identified through a literature search until January 24
th
 2015. 
Study selection: Randomised control trials (RCTs) of MRAs in patients with HF and/or left ventricular 
systolic dysfunction aged ≥65 years; or with sub-group analysis of patients ≥65 years; or with mean 
participant age ≥70 years.  
Data extraction and synthesis: Efficacy outcomes were mortality, hospitalisation for cardiovascular 
causes, symptom status or functional capacity. Safety outcomes were hyperkalaemia and renal 
dysfunction. Data were analysed using relative risk ratios with 95% confidence intervals. Relative risk 
ratios were pooled where more than three estimates were available. 
Results: Seven RCTs were included (total n=8638). Three RCTs in HF with reduced ejection fraction 
(HEFREF) reported overall benefit from MRA therapy with no significant treatment interaction for age; 
the effects of MRAs on mortality in patients ≥75 years displayed marked inter-study heterogeneity. In 
four RCTs of HF with preserved ejection fraction (HEFPEF), MRA treatment had no significant effect on 
any efficacy outcome. 
Conclusions: MRAs improve clinical outcomes in selected cohorts of older patients with HEFREF but 
not HEFPEF. In patients ≥75 years with HEFREF, the effect of MRA treatment on overall mortality is 







































































Heart failure (HF) is an increasing global public health problem that results in premature mortality, 
recurrent hospitalisation and debilitating symptoms and imposes a huge economic burden on healthcare 
resources.[1] Increasingly, HF represents a disease of older people with a population prevalence of 9-10% 
in individuals aged 75-84, and 17-18% in those 85 and older, compared with <1% in patients <65 
years.[2] Within the UK, the median age of patients hospitalised with HF is now 80 years.[3]  
 
Despite major advances in evidence-based treatments for HF with reduced ejection fraction (HEFREF), 
older patients remain under-represented in clinical trials and have substantially worse outcomes than 
younger patients.[4-6] Age related physiological changes, comorbidity, frailty, polypharmacy and altered 
drug pharmacokinetics may all attenuate the potential benefit from drug therapy in elderly HF patients 
and increase the risk of side effects and complications.[7] Moreover, the prevalence of HF with preserved 
ejection fraction (HEFPEF), a condition with a lack of proven therapies, is proportionately far greater in 
the elderly HF population.[6,  8-9] It is therefore essential to know whether recommended treatments are 
efficacious and safe for older people.  
 
Mineralcorticoid receptor antagonists (MRAs) have been shown to reduce mortality and hospitalisation in 
several cohorts of patients with HEFREF[12-14] and have recently been tested in patients with 
HEFPEF.[15,16] To date there has been no dedicated systematic review of the effects of MRA treatment 
in older patients with HF. We therefore sought to clarify the efficacy and safety of MRAs in older HF 
patients with both reduced and preserved ejection fraction.  


































































Search Strategy and Selection Criteria 
We performed a systematic review, and report it using the PRISMA (Preferred Reporting Items for 
Systematic reviews and Meta-Analyses) guidelines.[17] Retrieved results were filtered to include 
randomised controlled trials (RCTs) that fulfilled one or more of the following conditions: i) enrolled 
only patients aged ≥65 years, ii) included sub-group analysis of patients aged ≥65 years or iii) had a mean 
participant age of ≥70 years. The drugs of interest were spironolactone, epleronone and canrenone. Trials 
were required to include patients with HF of any aetiology and/or left ventricular systolic dysfunction 
(LV ejection fraction <40%) and to report at least one relevant clinical efficacy or safety outcome. The 
primary efficacy outcome was all cause mortality. Secondary efficacy outcomes were cardiovascular 
mortality, hospitalisation for cardiovascular causes, symptom status (validated quality of life assessment 
tools, New York Heart Association (NYHA) class), or functional capacity (6 minute walk test, VO2 max). 
Safety outcomes were hyperkalaemia and renal dysfunction, defined as per the primary trial publication. 
 
Data source and Study Search 
The following databases were searched MEDLINE (Ovid platform 1946 to January 24
th
 2015); EMBASE 
(Ovid platform 1980 to January 24
th
 2015); and CINAHL (Ebsco platform 1937 to January 24
th
 2015). 
Reference lists of the included RCTs and identified review articles were hand searched to find other 
potentially eligible studies. To ensure a large safety net, a sensitive search strategy was employed. We 
searched using a combination of MeSH headings and keywords (and their derivatives): mineralocorticoid 
receptor antagonist, aldosterone antagonist, spironolactone, epleronone, canrenone, heart failure, 
ventricular dysfunction (see also Appendix 1 in the supplementary data on the journal website 
http://www.ageing.oxfordjournals.org/). No language restrictions were applied. We searched for grey 
literature using Google and Google Scholar and also specifically searched for the drugs of interest on the 
websites of the United States Food and Drug Administration, other European and international health 

































































regulatory authorities. We searched clinical trials registers (https://clinicaltrials.gov; 
www.clinicaltrialsregister.eu) for ongoing and unpublished trials.   
 
The search of electronic databases was conducted by two independent reviewers who identified 
potentially relevant articles based on title or title and abstract. Full text articles were then retrieved for 
further assessment to determine whether they met inclusion criteria. Discrepancies were resolved by 
consensus. 
 
Quality Assessment and Data Extraction  
Relevant data were extracted and entered into a data collection form. Where available, outcomes data 
were extracted specifically for ‘younger elderly’ (65-74 years) and ‘older elderly’ (≥75 years) patients, as 
well as for patients with HEFREF and HEFPEF. Studies were assessed for quality using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system[18], with scoring 
performed by two independent authors and differences resolved by consensus.  
 
This systematic review was registered with PROSPERO, the international prospective register of 
systematic reviews (registration number CRD42013004478). 
 
 
Data synthesis and analysis 
Relative risk ratios were pooled where more than three estimates were available. Most studies reported 
hazards ratios. Some studies only provided proportional data and in these cases we calculated relative risk 
estimates derived from two by two contingency tables. We assumed that the ‘true effect’ estimate would 
be the same across all studies and initially derived overall pooled estimates using a fixed-effects model. 
In those meta-estimates where there was a high degree of heterogeneity (I
2
> 30%) we also provided 
estimates derived from a random effects model. Treatment effects and derived meta-estimates are 

































































expressed as risk ratios ± 95% confidence intervals. Continuous variables, unless otherwise stated, were 
expressed as mean± SD. Meta-analysis was performed using RevMan 5.3 software (The Cochrane 






































































One thousand eight hundred and sixty four articles were identified by the initial search strategy and, of 
these, eight articles[12-16, 19-21] describing seven RCTs were included in the final review (Figure 1). A 
subgroup study of the EMPHASIS-HF high risk[19] reported a prespecified analysis of efficacy and 
safety outcomes in trial patients ≥75 years. The original trial publication[14] included a subgroup analysis 
for the primary outcome in patients ≥65 years and was therefore also included. Study characteristics and 
quality are shown in table 1. Quality was generally moderate or high and with one exception[20] the 
studies were double-blinded and placebo-controlled with sample size based on appropriate power 
calculations. Overall dropout rates were <20% in all but one[12] of the studies whilst the differential 
dropout rate between the two treatment arms was <10% in all. One trial included a prespecified subgroup 
study in patients ≥75 years[19] but otherwise, the studies containing subgroup analysis of older patients 
offered limited characterisation and outcome data specific to our population of interest; consequently, for 
the purposes of this review, their quality was graded as moderate. A comprehensive search of grey 
literature and regulatory health websites uncovered additional relevant data for three of the included 






Three trials in patients with HEFREF reported relevant mortality and hospitalisation outcomes (Table 1, 
Figure 2). All reported an overall benefit from MRA therapy with respect to the individual trial’s primary 
endpoint  with no significant treatment interaction for age (Table 1). As shown in Figure 2, the magnitude 
of treatment effect for these endpoints in older patients was broadly similar to that in younger patients. 
The major exception to this was in patients ≥75 years with post-MI HEFREF; in these patients there was 
no apparent benefit from eplerenone treatment for either of the two co-primary endopoints, however age 

































































≥75 years was not examined as a treatment interaction term. Additionally, in patients ≥75 years with 
stable NYHA class II HEFREF, the effect of eplerenone on the trial’s primary composite endpoint was 
driven entirely by a reduction in hospitalisation for HF with no difference in CV mortality between the 
two treatment arms. 
 
Even if not reported as primary endpoint we found data on all cause mortality data in patients ≥75 and 
<75 years  for all three HEFREF trials (Figure 3). In patients <75 years there was a substantial and highly 
significant reduction in mortality that was consistent across studies (OR 0.74; CI 0.66-0.83; P<0.00001; I
2
 
= 5%). In contrast, in patients ≥75 years, we observed marked heterogeneity between studies (I
2
 = 79%; P 
= 0.009). On a random effects model there was no significant reduction in mortality in this elderly 
population with MRA therapy (OR 0.8; CI 0.52-1.25; P = 0.33).  
 
Specific hospitalisation data for elderly patients was obtained for only one of the HEFREF studies.[19] 
Although not a prespecified analysis, eplerenone significantly reduced hospitalisation for HF (Figure 2) 
and for cardiovascular causes (HR 0.62; CI 0.47-0.82) in patients ≥75 years with chronic stable HEFREF 
and NYHA class II symptoms.  
 
We found no data on the effects of MRA treatment on quality of life and/or functional capacity outcomes 
in older patients with HEFREF. 
 
HEFPEF 
In the single trial of patients with HEFPEF that reported mortality and hospitalisation outcomes, MRA 
therapy did not significantly reduce the incidence of the individual trial’s primary composite outcome 
Table 1; Figure 2). Hazard ratios for older patients were similar to those of the overall trial population and 
there was no significant treatment interaction for age. 
 

































































Three RCTs, all in patients with HEFPEF, reported limited quality of life and/or functional capacity 





Our specified safety endpoints were obtained from three studies (please see the table Appendix 3 in the 
supplementary data on the journal website http://www.ageing.oxfordjournals.org/). In two large trials, the 
incidence of hyperkalaemia (K+≥5.5 mmol/L) in patients ≥75 years was increased by MRA treatment. 
However, further data from one of these trials and a small trial of patients with mean age 71 years 
suggested a low overall incidence of severe hyperkalaemia (K
+
≥6.0) or hospitalisation for hyperkalaemia 
with no significant difference in the frequency of these events between the two treatment arms. In one 
large trial, neither decline in eGFR from baseline nor incidence of hospitalisation for worsening renal 




This systematic review of MRA treatment in older patients with heart failure included seven RCTs with a 
total of 8,638 patients aged ≥65 years and >3,300 aged ≥75 years. Across the spectrum of HEFREF, we 
found no overall mortality benefit from MRA therapy in patients ≥75 years, however MRAs did improve 
clinical outcomes (mortality and/or hospitalisations) in older patients with chronic stable HEFREF and in 
younger elderly patients with post-MI LVSD. There was no evidence of benefit from MRA treatment in 
elderly patients with HEFPEF.  
 
An age threshold of 65 years is frequently used to define elderly patients in both clinical and research 
settings. This cutoff may no longer be appropriate in conditions such as heart failure where the vast 

































































majority of patients are >65 years. In contemporary population-based studies, the mean age of patients 
with HF is now 80 years;[22] by comparison, the mean age of participants among large RCTs included in 
this review ranged from 64 to 68 years and patients ≥75 years contributed less than one third of the 
combined trial population. Moreover, whilst other established therapies for HF including ACE inhibitors 
and beta-blockers appear to be beneficial in ‘younger’ elderly patients there is some evidence to suggest 
they are less effective in patients ≥75 years.[23-24] We therefore sought relevant outcomes data for 
patients ≥75 years as well as for all patients ≥65 years.  
 
Across three large RCTs of MRAs in distinctive HEFREF populations, we observed a consistent 
mortality reduction in patients <75 years. In the two trials for which data were available, treatment 
response in patients aged 65-74 years closely mirrored that of younger patients. In contrast, the effect of 
MRAs on mortality in older elderly patients displayed marked heterogeneity. In chronic stable HEFREF, 
MRA treatment caused a striking reduction in all-cause death in patients ≥75 years with NYHA class III-
IV symptoms. We were unable to ascertain the mode of death among specific age cohorts, however 
within the overall trial population, MRAs reduced both sudden death and death from progressive heart 
failure. In a subsequent trial in NYHA class II patients, MRA therapy had a neutral effect on mortality 
among patients ≥75 years but reduced hospitalisations for heart failure by over 40% This suggests that 
MRA treatment may serve to retard progression of heart failure in older patients with possible 
mechanisms including prevention of myocardial fibrosis and reduced sodium retention.[25] In contrast to 
chronic stable HEFREF, neither all-cause mortality nor the composite of CV mortality or CV 
hospitalisation was reduced by MRA treatment in patients ≥75 years with early post-MI LVSD.  
 
The above data suggest that the response to MRAs among the older elderly with HEFREF may depend 
upon the particular patient subtype. However, we were unable to explore several other potential sources 
for the observed variation in treatment effect. The three trials included in our meta-analysis, spanned a 
recruitment period of 15 years, during which time background drug and device therapy underwent 

































































considerable change. Indeed, the background use of beta-blockers in the trials varied from 10%[12] to 
87%.[14] The trials also employed two different investigational drugs (spironolactone and eplerenone) 
and had populations that differed with respect to comorbidities, LV ejection fraction and aetiology of 
LVSD. Compounding this, the baseline characteristics of elderly patients were available for only one of 
the studies. We therefore call for an individual patient data meta-analysis of these RCTs to further explore 
the sources of heterogeneity in treatment response to MRAs among the very elderly, as well as to clarify 
the effects in elderly patients <75 years and to evaluate other major outcomes of interest in elderly 
patients. Beyond this, subgroup analysis from the forthcoming trial of early post-MI spironolactone 
treatment [Aldosterone Blockade Early After Acute Myocardial Infarction, ALBATROSS, 
NCT01059136]  may provide further insights into the utility of MRAs in very elderly patients with post-
MI LVSD. 
 
No treatments have yet been convincingly shown to improve outcomes in HEFPEF, the predominant 
form of HF among older patients.[6, 26]. One large RCT with subgroup analysis in elderly patients 
reported the effects of MRA therapy on major clinical outcomes in HEFPEF.[16] Whilst MRA treatment 
did not reduce the primary composite outcome within the overall study population, interpretation of the 
results has been complicated by marked geographical variation with respect to both patient profile and 
treatment effect[27]. No such variation in response to treatment was observed by patient age and 
outcomes in both the very elderly and younger elderly patients appeared similar to those of non-elderly 
patients. We found limited data regarding the effects of MRAs on other efficacy outcomes in elderly 
HEFPEF patients however two trials showed no apparent benefit on exercise capacity. Further work is 
now required to determine whether distinct subpopulations of elderly patients with HEFPEF may derive 
benefit from MRA therapy. Future studies should ideally include more robust assessments of symptoms, 
functional capacity and quality of life in addition to mortality and hospitalisation outcomes. 
 
 

































































The available safety data in this review confirms an increased risk of hyperkalaemia with MRA treatment 
in patients ≥75 years. However, in the single large RCT for which comprehensive safety data were 
available, the rates of severe hyperkalaemia, hyperkalaemia requiring hospitalisation or hospitalisation for 
worsening renal function were all very low and did not differ from elderly patients in the placebo arm. 
Registry studies comprising real world patients have reported considerably higher rates of serious safety 
outcomes with MRA treatment in the elderly, particularly hyperkalaemia.[28-29] This may in part be 
explained by more indiscriminate use of MRAs in everyday clinical practice among patients at risk of 
complications. Indeed more than 30% of Medicare beneficiaries prescribed spironolactone shortly after 
the publication of the Randomised Aldactone Evaluation Study (RALES) would have been ineligible for 
inclusion in RALES on account of baseline renal function or serum potassium.[29] Whilst such real world 
studies reinforce the need for caution when prescribing MRAs to older patients, the limited data in this 
review, suggests that the risks of serious complications can be mitigated through careful patient selection, 
monitoring and dose adjustment. Future studies with large elderly representation should consider 





The number of studies identified was relatively small and we are unable to exclude the possibility of 
publication bias. Furthermore, the original trial publications relating to these studies contained very 
limited data specific to elderly patients and we had no access to the primary trial data. Much of the data 
included in the review was, therefore previously unpublished and obtained from formal assessments by 
regulatory health authorities available on publically accessible websites. Whilst this may also be viewed 
as a strength of our search process, the results obtained were unavoidably sparse and, in several areas, 
incomplete. This could be addressed by future individual patient data meta-analysis of the major MRA 
RCTs in HEFREF as well as further dedicated study of MRAs in specific elderly HF cohorts.  



































































We found little  evidence for the effects of MRAs on efficacy outcomes other than mortality, particularly 
in the setting of HEFREF. The absence of robust evidence for outcomes such as quality of life and 
symptom status is disappointing as their importance, relative to mortality, is likely to increase with 
advancing age. We urge greater inclusion of these  endpoints in subsequent trials, particularly those with 
major elderly representation. All of the included studies used either spironolactone or eplerenone. Further 
work is required to evaluate the effects of canrenone and the novel, non-steroidal MRA, finrenone, in 
older heart failure patients. 
 
 
The literature under-represents the main population of older people with HF, mostly in their 80s and 90s. 
The presence of certain comorbid conditions such as diabetes, chronic kidney disease and chronic 
obstructive pulmonary were frequently reported, however other comorbidities such as cognitive 




The effect of MRAs on all cause mortality in older patients is uncertain, but they improve several major 
clinical outcomes in older patients with chronic HEFREF and in those aged <75 years with post-MI 
LVSD. In contrast, there is no evidence to support MRA treatment in older patients with HEFPEF. Whilst 
MRAs increase the risk of mild hyperkalaemia, limited data do not suggest major safety concerns in 
carefully selected and monitored elderly patients. Further study, with efficacy and safety outcomes 
relevant to older people, is required, particularly the very elderly. 
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Figure 1. PRISMA flowchart of search strategy and study selection. 
 
  
Records identified through 
database search  
(n=2887) 
Additional records 
identified by other sources 
(n=4) 
Records screened after 
duplicates removed  
(n=1864) 
Studies included in 
qualitative data synthesis 
(n=8) 
Records excluded by title 
and abstract review  
(n=1828) 
Full text articles assessed 
for eligibility 




No analysis in elderly 
patients (n=19) 
No relevant efficacy or 
safety outcome (n=7) 
No control group (n=1) 
Treatment period <8 weeks 
(n=1) 


































































Figure 2. Absolute events and Risk/Hazard ratios for relevant mortality and hospitalisation endpoints.  
*Unless otherwise stated, data represent relative risk ratios derived from 2x2 contingency tables. ^Hazard ratios. 
  
 




















Pitt et al,1999  
(RALES)[12]: 
All cause mortality 
Zannad et al 2011 
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CV death or  
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(EPHESUS)[13]: 
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Figure 3. Meta-analysis of mineralocorticoid receptor antagonist treatment on all cause mortality in 
patients with heart failure and reduced ejection fraction. A: fixed effects model in patients ≥75 years; B 




























































































Inclusion Criteria Study population 
(N) 




Main findings for overall 
study 
Sub-group analysis in elderly 
patients 
Pitt et al, 1999 
(RALES)[12] 
Moderatea HEFREF: 
Stable NYHA III/IV 
LVEF < 35% 
Total: 1663 
65-74 yrs: 638 
≥75 yrs: 349 
Spironolactone (25-50 
mg) vs placebo; mean 
24 months 
All cause mortality HR 0.70 (0.60-0.82): 
spironolactone vs placebo 
(P<0.001)  
No treatment interaction for age 
≥67 vs <67 years. 
Pitt et al, 2003 
(EPHESUS)[13] 
Moderatea HEFREF: 
3-14 days post MI 
LVEF < 40% 
Clinical or radiological 
evidence of HFb 
Total: 6642 
65-74 yrs: 2014 
≥75 yrs: 1328 
Epleronone (25 – 50 
mg) vs placebo; mean 
16 months 
i) All cause 
mortality 
ii) CV death or CV 
hospitalisationc 
i) HR 0.85 (0.75-0.96); ii)  
HR 0.83 (0.72-0.94):  
eplerenone vs placebo 
(P<0.01 for both) 
No treatment interaction for age 
≥65 vs <65 years for either 
outcome 
Zannad et al, 2011 
(EMPHASIS-HF) [14]; 




Stable HF NYHA II 
LVEF < 30%d 
BNP>250pg/ml or  
HF hospitalization in last 12 
months 
Total: 2737 
65-74 yrs: 1197 
≥ 75 yrs: 657 
Eplerenone (25 – 50 
mg) vs placebo; mean 
21 months 
 
CV death or 
hospitalisation for 
HF 
HR 0.63 (0.54-0.74): 
eplerenone vs placebo 
(P<0.0001) 
No treatment interaction for age: 
≥65 vs <65 years or ≥75 vs <75 
years. 
HR 0.67 (0.49-0.88): eplerenone 
vs placebo in patients ≥75 years 
(P<0.0001) 
Edelmann et al, 2013 
(ALDO-DHF)[16] 
Moderatea HEFPEF: 
Stable NYHA II-III 
LVEF ≥ 50% 
Grade ≥1 Diastolic LV 
dysfunction or AF  
Peak VO2 ≤25ml/kg/min 
Total: 422 
≥ 67 yrs: 221 
Spironolactone 25mg 
vs placebo; 12 months 
Change in VO2 max 
(ml/min/kg) 
No significant treatment 
effect  
[+0.1 (-0.6 - +0.8): 
spironolactone vs placebo 
(P=0.82)] 
+0.15 (-0.8 - +1.10) vs placebo in 
patients ≥67 years; no treatment 
interaction for age ≥67 vs <67 
years 




LVEF ≥ 45% 
BNP>100pg/mle or  
HF hospitalization in last 12 
months 
Total: 3445 
65-74 yrs: 1194 
≥ 75 yrs: 948 
Spironolactone (15-45 
mg) vs placebo; mean 
39 months 
 
CV death, aborted 




No significant treatment 
effect. 
[HR 0.89 (0.77-1.04) 
spironolactone vs placebo 
(P=0.14)]  
65-74 years: HR 1.01 (0.78-1.31) 
≥75 years: HR 0.88 (0.69-1.13) 
No treatment interaction for age 
(P=0.36)  
Mak et al, 2009 [20]. Moderatef HEFPEF: 
Symptomatic HF 
BNP > 100 pg/mL 
LVEF > 45% 
Diastolic LV dysfunction  
44 (Mean age 
80±1.2 years) 
Eplerenone (25-50mg) 




No significant treatment 
effect. [-2 (eplerenone) vs +2 
(control); P=NS 
N/A 
Kurrelmeyer et al, 2014 
[21] 
Moderatef HEFPEF: 
NYHA class II-III HF 
BNP > 62 pg/mL 
LVEF ≥50% 
Diastolic LV dysfunction 
48 (Mean age 
71±1.9 years) 
Spironolactone 25mg 
vs placebo; 6 months 
i) Change in 6 min 
walk (m) 
ii) Change in KCCQ 
clinical score 
i) +22m (spironolactone) vs 
+28m (placebo); P=NS 
ii) +2.3 (spironolactone) vs 
+7.6 (placebo); P=NS 
N/A 































































HF = heart failure; NYHA = New York Heart Association; LVEF = left ventricular ejection fraction; HR = Hazard ratio; MI = myocardial infarction; CV = 
cardiovascular; BNP = brain natriuretic peptide; AF = atrial fibrillation; MLWHFQ = Minnesota living with heart failure questionnaire; KCCQ = Kansas 
City cardiomyopathy questionnaire. 
a
Downgraded due to indirectness. 
b




Or N-terminal pro-BNP ≥500 
pg/ml (men) or ≥750 pg/ml (women). 
e
Or N-terminal pro-BNP ≥360 pg/ml. 
f
Downgraded due to risk of bias 


































































































































Appendix 3. Medline Search Strategy 
1. exp Heart Failure/ 
2. heart failure*.tw. 
3. exp Ventricular Dysfunction/  
4. 1 or 2 or 3 
5. exp Mineralocorticoid Receptor Antagonists/ 
6. aldosterone antagonist/  
7. mineralocorticoid receptor antagonist*.tw.  
8. aldosterone receptor antagonist*.tw.  
9. spironolactone/ or spironolactone.mp 
10. eplerenone.mp 
11. canrenone.mp 
12. 5 or 6 or 7 or 8 or 9 or 10 or 11 
13. randomized controlled trial.pt. 
14. controlled clinical trial.pt. 
15. randomized controlled trials/ 
16. random allocation/ 
17. double blind method/ 
18. single blind method/ 
19. 12 or 13 or 14 or 15 or 16 or 17 or 18 
20. limit 19 to animal 
21. limit 19 to human 
22. 20 and 21 
23. 20 not 22 
24. 19 not 23 
25. clinical trial.pt. 
26. exp clinical trials/ 




31. exp research design/ 
32. 25 or 26 or 27 or 28 or 29 or 30 or 31 
33. limit 32 to animal 
34. limit 32 to human 
35. 33 and 34 
36. 33 not 35 
37. 32 not 36 
38. comparative study/ 
39. exp evaluation studies/ 
































































40. follow-up studies/ 
41. prospective studies/ 
42. (control$ or prospectiv$ or volunteer$).tw.  
43. 38 or 39 or 40 or 41 or 42 
44. limit 43 to animal 
45. limit 43 to human 
46. 44 and 45 
47. 44 not 46 
48. 43 not 47 
49. 24 or 37 or 48 
50. 4 and 12 
51. 49 and 50 
 










































































Primary publication Additional efficacy data and source Additional safety data and 
source 
Pitt et al, 1999[12] Number of trial patients aged ≥65 years in each 
treatment arma 
Number of patients aged ≥65 years in each 
treatment arm with primary endpoint (all-cause 
mortality)a 
  
Percentage of trial patients aged ≥75 years in 
each treatment arm.b 
Percentage of patients aged ≥75 years in each 
treatment arm with primary endpointb  
 
Pitt et al, 2003[13] Number of trial patients aged ≥65 years in each 
treatment arm.a 
Number of patients aged ≥65 years in each 
treatment arm witha: 
i) all-cause mortality 
ii) CV death or CV hospitalisation 
 
Percentage of trial patients aged ≥75 years in 
each treatment arm.c 
Percentage of patients aged ≥75 years in each 
treatment arm withc: 
i) all-cause mortality 
ii) CV death or CV hospitalisation 
Percentage of patients aged ≥75 
years in each treatment arm with 
hyperkalaemia (serum K+>5.5)d 
Zannad et al, 2011[14];  
Eschalier et al, 
2013[19] 
Number of patients ≥75 years in each treatment 
arm withd:  
i) all cause mortality  
ii) hospitalisation for HF  
iii) cardiovascular hospitalisation  
Number of patients ≥75 years in 
each treatment arm withd:  
i) hospitalisation for 
hyperkalaemia  
ii) hospitalisation for WRF  
































































Table 2: Safety outcomes in elderly patients 






Hospitalisation for WRF 




























- - - - 
Pitt et al, 
200313† 
21.5%* 12.7% - - - - - - 
MRA = mineralcorticoid receptor antagonist; WRF = worsening renal function. 
*P<0.05 for MRA vs Placebo. †absolute numbers not available 
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